LT3161004T - Kovalentiškai sujungti diakūnai, pasižymintys imunoreaktyvumu pd-1 ir lag-3 bei jų naudojimo būdai - Google Patents
Kovalentiškai sujungti diakūnai, pasižymintys imunoreaktyvumu pd-1 ir lag-3 bei jų naudojimo būdaiInfo
- Publication number
- LT3161004T LT3161004T LTEP15811659.0T LT15811659T LT3161004T LT 3161004 T LT3161004 T LT 3161004T LT 15811659 T LT15811659 T LT 15811659T LT 3161004 T LT3161004 T LT 3161004T
- Authority
- LT
- Lithuania
- Prior art keywords
- immunoreactivity
- lag
- methods
- covalently bonded
- diabodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017467P | 2014-06-26 | 2014-06-26 | |
| PCT/US2015/036634 WO2015200119A1 (en) | 2014-06-26 | 2015-06-19 | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3161004T true LT3161004T (lt) | 2021-02-10 |
Family
ID=54938685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15811659.0T LT3161004T (lt) | 2014-06-26 | 2015-06-19 | Kovalentiškai sujungti diakūnai, pasižymintys imunoreaktyvumu pd-1 ir lag-3 bei jų naudojimo būdai |
Country Status (35)
Families Citing this family (208)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP3409278B8 (en) | 2011-07-21 | 2020-11-04 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| MX385338B (es) | 2013-02-22 | 2025-03-18 | CureVac SE | Combinación de vacunación e inhibición de la trayectoria pd-1. |
| JP2016531907A (ja) * | 2013-08-02 | 2016-10-13 | アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． | 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ |
| AU2014361473B2 (en) | 2013-12-12 | 2019-09-26 | Jiangsu Hengrui Medicine Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| TWI693232B (zh) * | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| MX382549B (es) | 2014-08-12 | 2025-03-13 | Alligator Bioscience Ab | Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1. |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN107484416A (zh) * | 2014-09-26 | 2017-12-15 | 宏观基因有限公司 | 能够结合cd19和cd3的双特异性单价双抗体及其用途 |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| TR201911032T4 (tr) | 2015-05-18 | 2019-08-21 | Tolero Pharmaceuticals Inc | Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları. |
| RS60792B1 (sr) | 2015-05-29 | 2020-10-30 | Agenus Inc | Anti-ctla-4 antitela i postupci za njihovu primenu |
| SMT202100527T1 (it) | 2015-07-30 | 2021-11-12 | Macrogenics Inc | Molecole di legame a pd-1 e lag-3 e loro metodi d'uso |
| CN108289953B (zh) | 2015-09-29 | 2022-03-11 | 细胞基因公司 | Pd-1结合蛋白及其使用方法 |
| EP3954709A1 (en) | 2015-10-02 | 2022-02-16 | F. Hoffmann-La Roche AG | Bispecific antibodies specific for pd1 and tim3 |
| PE20181300A1 (es) | 2015-11-02 | 2018-08-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| KR102220275B1 (ko) | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
| MX2018007089A (es) | 2015-12-14 | 2019-01-30 | Macrogenics Inc | Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas. |
| AU2016371639A1 (en) | 2015-12-16 | 2018-06-28 | Merck Sharp & Dohme Llc | Anti-LAG3 antibodies and antigen-binding fragments |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| AU2017219254B2 (en) | 2016-02-17 | 2019-12-12 | Novartis Ag | TGFbeta 2 antibodies |
| TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| NZ749355A (en) | 2016-05-27 | 2023-04-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
| US20200255524A1 (en) * | 2016-06-07 | 2020-08-13 | Macrogenics, Inc. | Combination therapy |
| AU2017283480A1 (en) | 2016-06-13 | 2019-01-24 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| CA3027302A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Beta Limited | Binding members(1) |
| AU2017283181B2 (en) | 2016-06-20 | 2024-08-15 | F-Star Therapeutics Limited | Binding molecules binding PD-L1 and LAG-3 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| EA201990747A1 (ru) | 2016-09-19 | 2019-10-31 | Способы лечения иммунных нарушений с применением белков, связывающих pd–1 | |
| US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
| TWI843168B (zh) | 2016-10-11 | 2024-05-21 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| WO2018083087A2 (en) * | 2016-11-02 | 2018-05-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Binding proteins |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| MD3551660T2 (ro) | 2016-12-07 | 2024-03-31 | Agenus Inc | Anticorpi anti-CTLA-4 și procedee de utilizare a acestora |
| EP3551225A1 (en) | 2016-12-07 | 2019-10-16 | Agenus Inc. | Antibodies and methods of use thereof |
| WO2018127709A1 (en) | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| KR20190103226A (ko) | 2017-01-13 | 2019-09-04 | 아게누스 인코포레이티드 | Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법 |
| EP3570870A1 (en) | 2017-01-20 | 2019-11-27 | Novartis AG | Combination therapy for the treatment of cancer |
| KR102660715B1 (ko) | 2017-02-10 | 2024-04-26 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 이미지화를 위한 방사선 라벨링된 항-lag3 항체 |
| AU2018217963B2 (en) | 2017-02-10 | 2020-11-19 | Novartis Ag | 1-(4-amino-5-bromo-6-(1 H-pyrazol-1-yl)pyrimidin-2-yl)-1 H-pyrazol-4-ol and use thereof in the treatment of cancer |
| WO2018152687A1 (en) * | 2017-02-22 | 2018-08-30 | I-Mab | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
| CA3050614A1 (en) * | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
| UA125700C2 (uk) | 2017-04-03 | 2022-05-18 | Ф. Хоффманн-Ля Рош Аг | Імунокон'югати антитіла до pd-1 з мутантом il-2 |
| MA49038B1 (fr) | 2017-04-05 | 2025-01-31 | F. Hoffmann-La Roche Ag | Anticorps bispécifiques se liant particulièrement à pd1 et lag3 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| EA201992586A1 (ru) | 2017-04-28 | 2020-03-03 | Файв Прайм Терапьютикс, Инк. | Способы лечения с помощью полипептидов внеклеточного домена cd80 |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| SMT202300243T1 (it) | 2017-05-01 | 2023-11-13 | Agenus Inc | Anticorpi anti-tigit e relativi metodi d'uso |
| AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| WO2018217940A2 (en) * | 2017-05-24 | 2018-11-29 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| WO2018222711A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
| DK3631454T3 (da) | 2017-05-30 | 2023-12-04 | Bristol Myers Squibb Co | Behandling af lag-3 positive tumorer |
| JOP20190279A1 (ar) | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| AU2018287519B2 (en) | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
| MX2019015885A (es) | 2017-06-22 | 2020-09-10 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas. |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| KR20200022447A (ko) | 2017-06-27 | 2020-03-03 | 노파르티스 아게 | 항-tim-3 항체의 투여 요법 및 그의 용도 |
| TWI875679B (zh) * | 2017-07-06 | 2025-03-11 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
| WO2019018730A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF |
| JP2020536495A (ja) | 2017-08-30 | 2020-12-17 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｌａｇ−３抗体及びその使用 |
| JP7387585B2 (ja) | 2017-09-04 | 2023-11-28 | アジェナス インコーポレイテッド | 混合系統白血病（ｍｌｌ）特異的ホスホペプチドに結合するｔ細胞受容体およびその使用方法 |
| US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| JP2021502810A (ja) | 2017-11-13 | 2021-02-04 | クレッシェンド、バイオロジックス、リミテッドＣｒｅｓｃｅｎｄｏ Ｂｉｏｌｏｇｉｃｓ Ｌｉｍｉｔｅｄ | Ｃｄ１３７およびｐｓｍａに結合する分子 |
| US20200277378A1 (en) | 2017-11-16 | 2020-09-03 | Novartis Ag | Combination therapies |
| US20200371091A1 (en) | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| KR20200098590A (ko) * | 2017-12-12 | 2020-08-20 | 마크로제닉스, 인크. | 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도 |
| WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| TW201930591A (zh) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JP2021511793A (ja) * | 2018-01-31 | 2021-05-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体 |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| WO2019153200A1 (zh) * | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| US20200399383A1 (en) | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| GB201802573D0 (en) * | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| EP3768727A4 (en) * | 2018-03-20 | 2021-12-22 | Wuxi Biologics Ireland Limited. | NEW BIS SPECIFIC PD-1 / LAG-3 ANTIBODY MOLECULES |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| WO2019210055A2 (en) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
| CN118878692A (zh) * | 2018-05-16 | 2024-11-01 | 嘉立医疗科技(广州)有限公司 | 双特异性抗体组合物及其使用方法 |
| CA3100349A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN112384531B (zh) | 2018-06-01 | 2024-05-14 | 诺华股份有限公司 | 针对bcma的结合分子及其用途 |
| WO2019246142A1 (en) * | 2018-06-18 | 2019-12-26 | Haiming Chen | Soluble bispecific fusion proteins for cancer immunotherapy |
| JP2021527714A (ja) | 2018-06-20 | 2021-10-14 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | 抗ｐｄ−１抗体及びその使用 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CR20210001A (es) | 2018-07-10 | 2021-04-19 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2) |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| EP3820898B1 (en) | 2018-07-12 | 2025-09-03 | invoX Pharma Limited | Antibody molecules that bind cd137 and ox40 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| TWI861005B (zh) | 2018-07-12 | 2024-11-11 | 英商英沃克斯製藥有限公司 | 結合pd-l1及cd137的抗體分子 |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| CA3107660A1 (en) | 2018-07-26 | 2020-01-30 | Bristol-Myers Squibb Company | Lag-3 combination therapy for the treatment of cancer |
| WO2020044252A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
| WO2020049534A1 (en) | 2018-09-07 | 2020-03-12 | Novartis Ag | Sting agonist and combination therapy thereof for the treatment of cancer |
| WO2020079581A1 (en) | 2018-10-16 | 2020-04-23 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
| PT4445958T (pt) | 2018-10-19 | 2025-11-26 | Bristol Myers Squibb Co | Terapia de associação para melanoma |
| WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
| KR20210099066A (ko) | 2018-12-04 | 2021-08-11 | 스미토모 다이니폰 파마 온콜로지, 인크. | 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체 |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2020128613A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1beta binding antibodies |
| EP3898675A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome |
| JP7450622B2 (ja) | 2018-12-21 | 2024-03-15 | ヴァレリオ・セラピューティクス | 新規のコンジュゲートされた核酸分子及びその使用 |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| EP3898674A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| US20220089722A1 (en) * | 2018-12-29 | 2022-03-24 | Nantong Yichen Biopharma. Co. Ltd. | Heterodimeric fusion protein |
| JP7662528B2 (ja) | 2019-02-12 | 2025-04-15 | スミトモ ファーマ アメリカ， インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
| JP2022519385A (ja) | 2019-02-12 | 2022-03-23 | ノバルティス アーゲー | Ｔｎｏ１５５及びｐｄ－１阻害剤を含む医薬組合せ |
| ES2982474T3 (es) | 2019-02-15 | 2024-10-16 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos |
| JP7483732B2 (ja) | 2019-02-15 | 2024-05-15 | ノバルティス アーゲー | ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| JP7547360B2 (ja) | 2019-03-22 | 2024-09-09 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法 |
| WO2020216348A1 (en) * | 2019-04-26 | 2020-10-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| CN112079925B (zh) * | 2019-06-13 | 2025-04-25 | 上海健信生物医药科技有限公司 | 靶向lag-3的抗体和双特异性抗体及其用途 |
| US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
| CN114144429B (zh) * | 2019-07-16 | 2023-10-13 | 上海药明生物技术有限公司 | 针对pd-1和lag-3的双特异性抗体 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| AU2020335928A1 (en) | 2019-08-30 | 2022-02-17 | Agenus Inc. | Anti-CD96 antibodies and methods of use thereof |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| US20220348653A1 (en) | 2019-09-22 | 2022-11-03 | Bristol-Myers Squibb Company | Quantitative Spatial Profiling for LAG-3 Antagonist Therapy |
| IL292347A (en) | 2019-10-21 | 2022-06-01 | Novartis Ag | Combination treatments with ventoclax and tim-3 inhibitors |
| KR20220087498A (ko) | 2019-10-21 | 2022-06-24 | 노파르티스 아게 | Tim-3 억제제 및 그의 용도 |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| CN115942973A (zh) | 2019-11-08 | 2023-04-07 | 百时美施贵宝公司 | 用于黑色素瘤的lag-3拮抗剂疗法 |
| CN112813099A (zh) | 2019-11-15 | 2021-05-18 | 上海细胞治疗集团有限公司 | 一种在活化的t细胞中具有高活性的启动子 |
| WO2021102343A1 (en) | 2019-11-22 | 2021-05-27 | Sumitomo Dainippon Pharma Oncology, Inc. | Solid dose pharmaceutical composition |
| JP2023507190A (ja) | 2019-12-20 | 2023-02-21 | ノバルティス アーゲー | 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用 |
| IL294207A (en) * | 2019-12-23 | 2022-08-01 | Macrogenics Inc | Therapy for the treatment of cancer |
| CN114980902A (zh) | 2020-01-17 | 2022-08-30 | 诺华股份有限公司 | 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合 |
| KR20220139915A (ko) | 2020-02-06 | 2022-10-17 | 브리스톨-마이어스 스큅 컴퍼니 | Il-10 및 그의 용도 |
| CN115279374A (zh) | 2020-02-28 | 2022-11-01 | 诺华股份有限公司 | 包含达拉菲尼、erk抑制剂和raf抑制剂的三重药物组合 |
| BR112022021105A2 (pt) | 2020-04-21 | 2022-11-29 | Novartis Ag | Regime de dosagem para tratar uma doença modulada por csf-1r |
| CN114605544B (zh) * | 2020-06-05 | 2023-08-01 | 北京天广实生物技术股份有限公司 | Lag3抗体及其用途 |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| US20230321067A1 (en) | 2020-06-23 | 2023-10-12 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| WO2022009157A1 (en) | 2020-07-10 | 2022-01-13 | Novartis Ag | Lhc165 and spartalizumab combinations for treating solid tumors |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CA3193421A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| AU2021373366A1 (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| FI4267105T3 (fi) | 2020-12-28 | 2025-06-17 | Bristol Myers Squibb Co | Vasta-ainekoostumuksia ja niiden käyttömenetelmiä |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| US20240141060A1 (en) | 2021-01-29 | 2024-05-02 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| JP2024506839A (ja) | 2021-01-29 | 2024-02-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | キナーゼ阻害剤を用いてがんを処置する方法 |
| WO2022195551A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarkers for cancer and methods of use thereof |
| AU2022246593A1 (en) | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AU2022253474A1 (en) | 2021-04-08 | 2023-11-16 | Board Of Regents, The University Of Texas System | Compounds and methods for theranostic targeting of parp activity |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2022240741A1 (en) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| US20240327544A1 (en) | 2021-07-13 | 2024-10-03 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| CA3224890A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| WO2023084445A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Combination therapy for treating lung cancer |
| MX2024007300A (es) | 2021-12-16 | 2024-06-28 | Valerio Therapeutics | Nuevas moleculas de acido nucleico conjugado y sus usos. |
| JP2025503962A (ja) | 2022-01-26 | 2025-02-06 | ブリストル－マイヤーズ スクイブ カンパニー | 肝細胞がんのための併用療法 |
| IL314713A (en) | 2022-02-25 | 2024-10-01 | Bristol Myers Squibb Co | Combined therapy for colorectal carcinoma |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| US20250179170A1 (en) | 2022-03-08 | 2025-06-05 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| IL317319A (en) | 2022-06-02 | 2025-01-01 | Bristol Myers Squibb Co | Antibody compounds and methods of using them |
| AU2023403103A1 (en) | 2022-12-01 | 2025-07-10 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
| AU2023393653A1 (en) | 2022-12-14 | 2025-05-22 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| KR20250123912A (ko) | 2022-12-21 | 2025-08-18 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 병용 요법 |
| EP4665410A1 (en) | 2023-02-17 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2024216028A1 (en) | 2023-04-12 | 2024-10-17 | Agenus Inc. | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| TW202535926A (zh) | 2023-10-30 | 2025-09-16 | 美商再生元醫藥公司 | 穩定抗體配製物 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| WO2025184211A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025226695A1 (en) | 2024-04-23 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| JP2571874B2 (ja) | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス，インコーポレイテッド | タンパク質マイクロスフェア組成物 |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| IL108501A (en) | 1994-01-31 | 1998-10-30 | Mor Research Applic Ltd | Antibodies and pharmaceutical compositions containing them |
| ZA953629B (en) | 1994-05-06 | 1996-11-05 | Roussy Inst Gustave | Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies |
| AU4755696A (en) | 1995-01-05 | 1996-07-24 | Board Of Regents Acting For And On Behalf Of The University Of Michigan, The | Surface-modified nanoparticles and method of making and using same |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| CA2230494A1 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| KR100241009B1 (ko) | 1995-12-29 | 2000-03-02 | 이구택 | 용융환원공정에서의 미분광취입방법 |
| US5942328A (en) | 1996-02-29 | 1999-08-24 | International Business Machines Corporation | Low dielectric constant amorphous fluorinated carbon and method of preparation |
| JP2000506165A (ja) | 1996-03-04 | 2000-05-23 | ザ ペン ステイト リサーチ ファウンデーション | 細胞インターナリゼーションを増強するための物質および方法 |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| AU728911B2 (en) | 1996-11-28 | 2001-01-18 | Institut Gustave Roussy | Mutants of the LAG-3 proteins, products for the expression of these mutants and use |
| WO1998031346A1 (en) | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| EP0900841A1 (en) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| AU747231B2 (en) | 1998-06-24 | 2002-05-09 | Alkermes, Inc. | Large porous particles emitted from an inhaler |
| DE19834575C5 (de) | 1998-07-31 | 2009-05-20 | Valeo Klimasysteme Gmbh | Drehschieberventil |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| AU784062B2 (en) | 1999-08-23 | 2006-01-19 | Dana-Farber Cancer Institute, Inc. | Novel B7-4 molecules and uses therefor |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| JP4727886B2 (ja) | 1999-12-22 | 2011-07-20 | ノバダック テクノロジーズ インコーポレイテッド | 皮膚異常検出用可搬型システム |
| EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
| AR036993A1 (es) * | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| ES2276735T3 (es) | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| NZ535925A (en) | 2002-04-16 | 2008-06-30 | Genentech Inc | An isolated antibody that binds to a particular polypeptide |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| EP2308968A1 (en) | 2002-11-26 | 2011-04-13 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| JP4532409B2 (ja) | 2003-01-23 | 2010-08-25 | 小野薬品工業株式会社 | ヒトｐｄ−１に対し特異性を有する物質 |
| EP1897548B2 (en) | 2003-02-28 | 2024-05-22 | The Johns Hopkins University | T cell regulation |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| KR20050082389A (ko) | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
| US20070166281A1 (en) | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
| US20090123413A1 (en) | 2004-08-23 | 2009-05-14 | Britta Hardy | Use of bat monoclonal antibody for immunotherapy |
| KR20070050504A (ko) | 2004-10-15 | 2007-05-15 | 베리사인 인코포레이티드 | 일회용 비밀번호 |
| ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| US9963510B2 (en) * | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| NZ601439A (en) | 2005-06-08 | 2012-11-30 | Brigham & Womens Hospital | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
| JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| EP2937360A1 (en) * | 2005-06-17 | 2015-10-28 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| JP5090366B2 (ja) | 2005-12-16 | 2012-12-05 | アイビーシー ファーマスーティカルズ，インク． | 多価イムノグロブリン系生物活性アセンブリー |
| MX2008015524A (es) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
| NZ596237A (en) | 2006-12-27 | 2012-07-27 | Dana Farber Cancer Inst Inc | Compositions and methods for the treatment of infections and tumors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US8062852B2 (en) | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| MX2010005830A (es) | 2007-11-30 | 2010-09-14 | Bristol Myers Squibb Co | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. |
| CA2715166C (en) | 2008-02-11 | 2017-05-16 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| WO2010001617A1 (en) | 2008-07-04 | 2010-01-07 | Ono Pharmaceutical Co., Ltd. | Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| WO2010028795A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
| WO2010028797A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
| WO2010028796A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| MX348166B (es) | 2008-12-19 | 2017-06-01 | Macrogenics Inc | Diacuerpos covalentes y sus usos. |
| EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| CA2755640C (en) | 2009-03-20 | 2018-05-22 | Genentech, Inc. | Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr |
| MX2011011925A (es) | 2009-05-27 | 2011-12-06 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| US8876892B2 (en) | 2010-04-21 | 2014-11-04 | Medtronic, Inc. | Prosthetic heart valve delivery system with spacing |
| CA2796633C (en) | 2010-04-23 | 2020-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| SG187682A1 (en) | 2010-08-02 | 2013-03-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| KR20190116563A (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| WO2012156430A1 (en) | 2011-05-17 | 2012-11-22 | Trion Research Gmbh | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| MX347818B (es) * | 2011-05-21 | 2017-05-15 | Macrogenics Inc | Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero. |
| WO2012162583A1 (en) | 2011-05-26 | 2012-11-29 | Ibc Pharmaceuticals, Inc. | Design and construction of novel multivalent antibodies |
| US20150045540A1 (en) | 2011-06-28 | 2015-02-12 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
| PL2726101T3 (pl) | 2011-06-30 | 2019-01-31 | Genzyme Corporation | Inhibitory aktywacji komórek t |
| EP2729488A4 (en) | 2011-07-06 | 2015-01-14 | Medimmune Llc | PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES |
| EP2734551B1 (en) | 2011-07-24 | 2018-01-10 | Cure Tech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| CA2863944A1 (en) | 2012-02-10 | 2013-08-15 | Research Corporation Technologies, Inc. | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| HK1203517A1 (en) | 2012-05-24 | 2015-10-30 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN103566377A (zh) * | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| ES2848052T3 (es) | 2012-08-03 | 2021-08-05 | Dana Farber Cancer Inst Inc | Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso |
| WO2014028502A1 (en) * | 2012-08-13 | 2014-02-20 | ImmunGene Inc. | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
| KR102207767B1 (ko) | 2012-09-17 | 2021-01-26 | 갈렉틴 테라퓨틱스, 인크. | 암 치료에서의 특이적 면역요법을 강화하는 방법 |
| CA2887027C (en) | 2012-10-02 | 2021-11-16 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| EP3679950A1 (en) | 2012-10-12 | 2020-07-15 | The Brigham and Women's Hospital, Inc. | Enhancement of the immune response |
| WO2014066532A1 (en) | 2012-10-23 | 2014-05-01 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| IL240838B (en) | 2013-03-15 | 2022-09-01 | Glaxosmithkline Ip Dev Ltd | Anti-3–lag binding proteins |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| WO2015036394A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune Limited | Antibodies against pd-1 and uses thereof |
| HUE060420T2 (hu) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
| RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| NZ720353A (en) | 2013-12-30 | 2019-12-20 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
| US20170015758A1 (en) | 2014-01-21 | 2017-01-19 | Medimmune, Llc | Compositions And Methods For Modulating And Redirecting Immune Responses |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| EP3099716A1 (en) | 2014-01-28 | 2016-12-07 | Bristol-Myers Squibb Company | Anti-lag-3 antibodies to treat hematological malignancies |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| CN106714839A (zh) | 2014-05-15 | 2017-05-24 | 百时美施贵宝公司 | 使用抗pd‑1抗体和另一种抗癌剂的组合治疗肺癌 |
| WO2015195163A1 (en) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Pd-l1 antagonist fully human antibody |
| TWI693232B (zh) * | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| WO2015200828A1 (en) | 2014-06-27 | 2015-12-30 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
| NZ728688A (en) | 2014-07-22 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
| CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| CA2957258C (en) | 2014-08-05 | 2023-11-07 | MabQuest SA | Immunological reagents |
| RU2722212C9 (ru) | 2014-08-05 | 2020-07-23 | СиБи ТЕРЕПЬЮТИКС, ИНК. | Анти-pd-l1 антитела |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
| EP3218409A2 (en) | 2014-11-11 | 2017-09-20 | Sutro Biopharma, Inc. | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CA3175979A1 (en) | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| EA201791768A1 (ru) | 2015-02-06 | 2018-07-31 | КАДМОН КОРПОРЕЙШН, ЭлЭлСи | Иммуномодулирующие агенты |
| ES2813580T3 (es) | 2015-04-17 | 2021-03-24 | Bristol Myers Squibb Co | Composiciones que comprenden una combinación de ipilimumab y nivolumab |
| SMT202100527T1 (it) * | 2015-07-30 | 2021-11-12 | Macrogenics Inc | Molecole di legame a pd-1 e lag-3 e loro metodi d'uso |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
-
2015
- 2015-06-12 TW TW104119190A patent/TWI693232B/zh active
- 2015-06-19 WO PCT/US2015/036634 patent/WO2015200119A1/en not_active Ceased
- 2015-06-19 HU HUE15811659A patent/HUE052615T2/hu unknown
- 2015-06-19 UA UAA201700685A patent/UA119673C2/uk unknown
- 2015-06-19 AU AU2015280392A patent/AU2015280392B2/en active Active
- 2015-06-19 EP EP15811659.0A patent/EP3161004B1/en active Active
- 2015-06-19 CR CR20160599A patent/CR20160599A/es unknown
- 2015-06-19 LT LTEP15811659.0T patent/LT3161004T/lt unknown
- 2015-06-19 DK DK15811659.0T patent/DK3161004T3/da active
- 2015-06-19 PE PE2016002777A patent/PE20170767A1/es unknown
- 2015-06-19 HR HRP20210041TT patent/HRP20210041T1/hr unknown
- 2015-06-19 SG SG11201610715SA patent/SG11201610715SA/en unknown
- 2015-06-19 PL PL15811659T patent/PL3161004T3/pl unknown
- 2015-06-19 PT PT158116590T patent/PT3161004T/pt unknown
- 2015-06-19 MY MYPI2016002274A patent/MY177324A/en unknown
- 2015-06-19 US US15/321,279 patent/US10160806B2/en active Active
- 2015-06-19 JP JP2016575555A patent/JP6890421B2/ja active Active
- 2015-06-19 SI SI201531473T patent/SI3161004T1/sl unknown
- 2015-06-19 ES ES15811659T patent/ES2843269T3/es active Active
- 2015-06-19 CA CA2953818A patent/CA2953818C/en active Active
- 2015-06-19 EA EA201790087A patent/EA036737B1/ru not_active IP Right Cessation
- 2015-06-19 GE GEAP2015014392 patent/GEP20197034B/en unknown
- 2015-06-19 SM SM20210021T patent/SMT202100021T1/it unknown
- 2015-06-19 RS RS20210025A patent/RS61284B1/sr unknown
- 2015-06-19 CN CN201580034116.XA patent/CN106715470B/zh active Active
- 2015-06-19 KR KR1020177001638A patent/KR102514330B1/ko active Active
- 2015-06-19 MX MX2016017240A patent/MX369486B/es active IP Right Grant
- 2015-06-26 AR ARP150102058A patent/AR101009A1/es active IP Right Grant
-
2016
- 2016-12-20 ZA ZA2016/08768A patent/ZA201608768B/en unknown
- 2016-12-22 PH PH12016502590A patent/PH12016502590A1/en unknown
- 2016-12-23 EC ECIEPI201696342A patent/ECSP16096342A/es unknown
- 2016-12-25 IL IL249764A patent/IL249764B/en unknown
- 2016-12-25 SA SA516380600A patent/SA516380600B1/ar unknown
- 2016-12-26 CL CL2016003335A patent/CL2016003335A1/es unknown
-
2018
- 2018-11-13 US US16/189,071 patent/US11098119B2/en active Active
-
2019
- 2019-12-20 JP JP2019230058A patent/JP2020073506A/ja active Pending
-
2021
- 2021-01-12 CY CY20211100015T patent/CY1123917T1/el unknown
- 2021-07-14 US US17/375,821 patent/US20220041714A1/en not_active Abandoned
-
2025
- 2025-06-16 US US19/239,433 patent/US20250304685A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249764B (en) | Covalent diatoms that bind 1-pd and 3-lag and their use | |
| IL279606A (en) | Anti-TREM2 antibodies and methods of using them | |
| IL260021A (en) | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them | |
| IL251868B (en) | Anti-tim3 antibodies and methods of use | |
| IL251970A0 (en) | Anti-cd79b antibodies and methods of use | |
| ZA201800315B (en) | Anti-jagged1 antibodies and methods of use | |
| SG11201609721WA (en) | Anti-gitr antibodies and methods of use thereof | |
| HUE060165T2 (hu) | PD-1 elleni ellenanyagok és alkalmazásukra szolgáló eljárások | |
| IL247754A0 (en) | Antibodies against mcam and related methods of use | |
| IL251165A0 (en) | Anti-il-1beta antibodies and methods of their use | |
| IL247315A0 (en) | Anti-acth antibodies and their uses | |
| HK1236976A1 (en) | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof |